- Home
- DAWN vs INVH Comparison
DAWN vs INVH Comparison
Compare DAWN & INVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- INVH
- Stock Information
- Founded
- DAWN 2018
- INVH 2012
- Country
- DAWN United States
- INVH United States
- Employees
- DAWN N/A
- INVH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- INVH Real Estate
- Sector
- DAWN Health Care
- INVH Finance
- Exchange
- DAWN Nasdaq
- INVH Nasdaq
- Market Cap
- DAWN 1.3B
- INVH 20.9B
- IPO Year
- DAWN 2021
- INVH 2017
- Fundamental
- Price
- DAWN $12.79
- INVH $32.26
- Analyst Decision
- DAWN Strong Buy
- INVH Buy
- Analyst Count
- DAWN 7
- INVH 20
- Target Price
- DAWN $36.17
- INVH $38.75
- AVG Volume (30 Days)
- DAWN 1.0M
- INVH 3.5M
- Earning Date
- DAWN 10-30-2024
- INVH 02-11-2025
- Dividend Yield
- DAWN N/A
- INVH 3.48%
- EPS Growth
- DAWN N/A
- INVH N/A
- EPS
- DAWN N/A
- INVH 0.72
- Revenue
- DAWN $101,953,000.00
- INVH $2,554,563,000.00
- Revenue This Year
- DAWN N/A
- INVH N/A
- Revenue Next Year
- DAWN $36.10
- INVH $4.86
- P/E Ratio
- DAWN N/A
- INVH $44.77
- Revenue Growth
- DAWN N/A
- INVH 7.65
- 52 Week Low
- DAWN $11.94
- INVH $31.01
- 52 Week High
- DAWN $18.07
- INVH $37.80
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- INVH 34.70
- Support Level
- DAWN $12.26
- INVH $31.58
- Resistance Level
- DAWN $12.81
- INVH $33.63
- Average True Range (ATR)
- DAWN 0.52
- INVH 0.56
- MACD
- DAWN -0.05
- INVH -0.20
- Stochastic Oscillator
- DAWN 28.94
- INVH 16.16
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of nearly 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.